Irritable bowel syndrome and inflammatory bowel disease: Is there an overlap?

Practical Gastroenterology

Volumn 34, Issue 11, 2010, Pages 31-37

  Quigley, Eamonn M M ^a   Shanahan, Fergus ^a  

^a UNIVERSITY COLLEGE CORK   (Ireland)

Author keywords

[No Author keywords available]

Indexed keywords

CALGRANULIN; INTERLEUKIN 6; INTERLEUKIN 8;

ARTICLE; CHRONIC INFLAMMATION; CLOSTRIDIUM DIFFICILE INFECTION; CROHN DISEASE; CYTOKINE PRODUCTION; DISEASE ASSOCIATION; DISEASE CLASSIFICATION; DISEASE COURSE; HUMAN; IMMUNOPATHOGENESIS; INTESTINE FLORA; IRRITABLE COLON; MUCOSAL IMMUNITY; NONHUMAN; PROTEIN BLOOD LEVEL; QUALITY OF LIFE; REMISSION; T LYMPHOCYTE SUBPOPULATION; ULCERATIVE COLITIS;

EID: 79551706101     PISSN: 02774208     EISSN: None     Source Type: Journal    
DOI: None     Document Type: Article

References (40)

1. Hungin AP, Chang L, Locke GR, Dennis EH, Barghout V. Irritable bowel syndrome in the United States: prevalence, symptom patterns and impact. Aliment Pharmacol Ther. 2005;21:1365-75.
2. Hungin APS, Whorwell PJ, Tack J, Mearin F. The prevalence, patterns and impact of irritable bowel syndrome: an international survey of 40,000 subjects. Aliment Pharmacol Ther. 2003;17: 643-50.
3. Quigley EMM, Bergmann J-F, Bytzer P, Fried M, Hunt R, Hungin APS, Kellow J, Koch G, Laine L, Schoenfeld P, Spiegel BMR, Tack J, Tytgat G. An evidence-based approach to the management of irritable bowel syndrome in Europe. Eur J Gastroenterol Hepatol 19(suppl 1):S1-S37, 2007.
4. Bernstein CN, Wajda A, Svenson LW, MacKenzie A, Koehoorn M, Jackson M, Fedorak R, Israel D, Blanchard JF. The epidemiology of inflammatory bowel disease in Canada: a populationbased study. Am J Gastroenterol. 2006;101:1559-68.
5. Thabane M, Kottachchi DT, Marshall JK. Systematic review and meta-analysis: The incidence and prognosis of post-infectious irritable bowel syndrome. Aliment Pharmacol Ther. 2007;26: 535-44.
6. Spiller R, Garsed K. Postinfectious irritable bowel syndrome. Gastroenterology. 2009;136:1979-88.
7. Villani AC, Lemire M, Thabane M, Belisle A, Geneau G, Garg AX, Clark WF, Moayyedi P, Collins SM, Franchimont D, Marshall JK. Genetic risk factors for post-infectious irritable bowel syndrome following a waterborne outbreak of gastroenteritis. Gastroenterology. 2010;138:1502-13.
8. Craig OF, Quigley EMM. Bacteria, Genetics and Irritable Bowel Syndrome (IBS). Expert Rev Gastroenterol 2010; (in press).
9. Clayton EM, Rea MC, Shanahan F, Quigley EM, Kiely B, Hill C, Ross RP. The vexed relationship between Clostridium difficile and inflammatory bowel disease: an assessment of carriage in an outpatient setting among patients in remission. Am J Gastroenterol 2009;104:1162-9.
10. Gradel KO, Nielsen HL, Schønheyder HC, Ejlertsen T, Kristensen B, Nielsen H. Increased short-and long-term risk of inflammatory bowel disease after salmonella or campylobacter gastroenteritis. Gastroenterology. 2009;137:495-501.
11. Quigley EMM. Do patients with functional gastrointestinal disorders have an altered flora? Ther Adv Gastroenterol 2009; 2(suppl 1):S23-S30.
12. Dinan TG, Quigley EMM, Ahmed SMM, Scully P, O'Brien S, O'Mahony L, O'Mahony S, Shanahan F, Keeling PWN. Hypothalamic-pituitary-gut axis dysregulation in irritable bowel syndrome: plasma cytokines as a potential biomarker? Gastroenterology 2006;130:304-311.
13. Liebregts T, Adam B, Bredack C, et al. Immune activation in patients with irritable bowel syndrome. Gastroenterology 2007;132:913-20.
14. Scully P, McKernan DP, Keohane J, Groeger D, Shanahan F, Dinan TG and Quigley EMM. Plasma cytokine profiles in females with irritable bowel syndrome and extra-intestinal co-morbidity. Am J Gastroenterol Apr 20. [Epub ahead of print.
15. Barbara G, Stanghellini V, De Giorgio R, Cremon C, Cottrell GS, Santini D, et al. Activated mast cells in proximity to colonic nerves correlate with abdominal pain in irritable bowel syndrome. Gastroenterology 2004;126:693-702.
16. Barbara G, Wang B, Stanghellini V, de Giorgio R, Cremon C, Di Nardo G, et al. Mast cell-dependent excitation of visceralnociceptive sensory neurons in irritable bowel syndrome. Gastroenterology 2007;132:26-37.
17. Cenac N, Andrews CN, Holzhausen M, Chapman K, Cottrell G, Andrade-Gordon P, Steinhoff M, Barbara G, Beck P, Bunnett NW, Sharkey KA, Ferraz JG, Shaffer E, Vergnolle N. Role for protease activity in visceral pain in irritable bowel syndrome. J Clin Invest. 2007;117:636-47.
18. Guilarte M, Santos J, de Torres I, Alonso C, Vicario M, Ramos L, Martinez C, Casellas F, Saperas E, Malagelada JR. Diarrhoeapredominant IBS patients show mast cell activation and hyperplasia in the jejunum. Gut. 2007;56:203-9.
19. Buhner S, Li Q, Vignali S, Barbara G, De Giorgio R, Stanghellini V, Cremon C, Zeller F, Langer R, Daniel H, Michel K, Schemann M. Activation of human enteric neurons by supernatants of colonic biopsy specimens from patients with irritable bowel syndrome. Gastroenterology. 2009;137:1425-34.
20. Chadwick V, Chen W, Shu D et al. Activation of the mucosal immune system in irritable bowel syndrome. Gastroenterology 2002; 122: 1778-83.
21. Holmen N, Isaksson S, Simren M, Sjovall H, Ohman L. CD4+CD25+ regulatory T cells in irritable bowel syndrome patients. Neurogastroenterol Motil. 2007;19:119-25.
22. Ohman L, Isaksson S, Lundgren A, Simren M, Sjovall H. A controlled study of colonic immune activity and beta7+ blood T lymphocytes in patients with irritable bowel syndrome. Clin Gastroenterol Hepatol. 2005;3:980-6.
23. Cremon C, Gargano L, Morselli-Labate AM, Santini D, Cogliandro RF, De Giorgio R, Stanghellini V, Corinaldesi R, Barbara G. Mucosal immune activation in irritable bowel syndrome: genderdependence and association with digestive symptoms. Am J Gastroenterol. 2009;104:392-400.
24. Quigley E. Gut permeability in irritable bowel syndrome: more leaks add to slightly inflamed bowel syndrome conspiracy theory. Gastroenterology. 2009;137:728-30.
25. Barbara G. Mucosal barrier defects in irritable bowel syndrome. Who left the door open? Am J Gastroenterol 2006;101: 1295-8.
26. MacSharry J, O'Mahony L, Fanning A, Bairead E, Sherlock G, Tiesman J, Fulmer A, Kiely B, Dinan TG, Shanahan F, Quigley EM. Mucosal cytokine imbalance in irritable bowel syndrome. Scand J Gastroenterol. 2008;43:1467-76.
27. Aerssens J, Camilleri M, Talloen W, Thielemans L, Göhlmann HW, Van Den Wyngaert I, Thielemans T, De Hoogt R, Andrews CN, Bharucha AE, Carlson PJ, Busciglio I, Burton DD, Smyrk T, Urrutia R, Coulie B. Alterations in mucosal immunity identified in the colon of patients with irritable bowel syndrome. Clin Gastroenterol Hepatol. 2008;6:194-205.
28. Brint EK, MacSharry J, Fanning A, Shanahan F, Quigley EMM. Differential Expression of Toll-Like Receptors (TLRs) in patients with Irritable Bowel Syndrome. Am J Gastroenterol. 2010 (in press).
29. Langhorst J, Junge A, Rueffer A, Wehkamp J, Foell D, Michalsen A, Musial F, Dobos GJ. Elevated human beta-defensin-2 levels indicate an activation of the innate immune system in patients with irritable bowel syndrome. Am J Gastroenterol. 2009;104: 404-10.
30. Keohane J, O'Mahony C, O'Mahony L, O'Mahony S, Quigley EM, Shanahan F. Irritable Bowel Syndrome-Type Symptoms in Patients With Inflammatory Bowel Disease: A Real Association or Reflection of Occult Inflammation? Am J Gastroenterol. 2010 Apr 13. [Epub ahead of print]
31. Burgmann T, Clara I, Graff L, Walker J, Lix L, Rawsthorne P, McPhail C, Rogala L, Miller N, Bernstein CN. The Manitoba Inflammatory Bowel Disease Cohort Study: prolonged symptoms before diagnosis-how much is irritable bowel syndrome? Clin Gastroenterol Hepatol. 2006;4:614-20.
32. Brandt LJ, Bjorkman D, Fennerty MB, Locke GR, Olden K, Peterson W, Quigley E, Schoenfeld P, Schuster M, Talley N. Systematic review on the management of irritable bowel syndrome in North America. Am J Gastroenterol 2002;97(Suppl II):S7-S26.
33. Pardi DS, Ramanath VR, Loftus EV, Tremaine WJ, Sandborn WJ. Lymphocytic colitis: clinical features, treatment, and outcomes. Am J Gastroenterol 2002;97:2829-2833.
34. Isgar B, Harmann M, Kaye MD, Whorwell PJ. Symptoms of irritable bowel syndrome in ulcerative colitis in remission. Gut 1983;24:190-192.
35. Simren M, Axelsson J, Gillberg R, Abrahamsson H, Svedlund J, Bjornsson ES. Quality of life in inflammatory bowel disease in remission: the impact of IBS-like symptoms and associated psychological factors. Am J Gastroenterol 2002;97:389-396.
36. Shen B, Achkar J-P, Lashner BA, Ormsby AH, Brzezinski A, Soffer EE, Remzi FH, Bevins CL, Fazio VW. Irritable pouch syndrome: a new category of diagnosis for symptomatic patients with ileal pouch-anal anastomosis. Am J Gastroenterol 2002; 97:972-977.
37. Geboes K, Collins S. Structural abnormalities of the nervous system in Crohn's disease and ulcerative colitis. Neurogastroenterol Mot. 1998;10:189-202.
38. Shanahan F. Enteric neuropathology and inflammatory bowel disease. Neurogastroenterol Mot. 1998;10:185-187.
39. Collins SM. The immunomodulation of enteric neuromuscular function: implications for motility and inflammatory disorders. Gastroenterology 1996;111:1683-1699.
40. Schoepfer AM, Beglinger C, Straumann A, Trummler M, Vavricka SR, Bruegger LE, Seibold F. Fecal calprotectin correlates more closely with the Simple Endoscopic Score for Crohn's disease (SES-CD) than CRP, blood leukocytes, and the CDAI. Am J Gastroenterol. 2010;105:162-9.